Zavegepant

Zavegepant
Names
Trade namesZavzpret
Other namesBHV-3500
IUPAC name
  • N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
Clinical data
Drug classCalcitonin gene-related peptide receptor antagonist[1]
Main usesMigraine headaches[1]
Side effectsTaste changes, nausea, sore nose, vomiting[1]
Routes of
use		Nasal
Typical dose10 mg[1]
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status
Chemical and physical data
FormulaC36H46N8O3
Molar mass638.817 g·mol−1
3D model (JSmol)
SMILES
  • CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O
InChI
  • InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
  • Key:JJVAPHYEOZSKJZ-JGCGQSQUSA-N
  • Key:VQDUWCSSPSOSNA-RYWNGCACSA-N

Zavegepant, sold under the brand name Zavzpret, is a medication used to treat migraine headaches.[1] It is used for the headache itself, rather than prevention.[1] It is sprayed into the nose.[1]

Common side effects include taste changes, nausea, sore nose, and vomiting.[1] Other side effects include allergic reactions.[1] Use is not recommended in people with significant liver or kidney problems.[1] Safety in pregnancy is unclear.[1] It is a calcitonin gene-related peptide receptor antagonist.[1]

Zavegepant was approved for medical use in the United States in 2023.[1] It is expected to become commercially available in July of 2023 and be priced similar to other medications in its class.[2]

Medical uses

Zavegepant is indicated for the acute treatment of migraine with or without aura in adults.[1]

Dosage

It is given at a dose of 10 mg, with at most one dose per day.[1]

Society and culture

It is sold by Pfizer.[1]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 "ZAVZPRET™ (zavegepant) nasal spray" (PDF). Archived (PDF) from the original on 2023-03-11. Retrieved 2023-03-13.
  2. ↑ MSc, Nadia Stec (14 March 2023). "Zavzpret (Zavegepant) Migraine Nasal Spray from Pfizer Gets FDA Nod". Xtalks. Archived from the original on 15 March 2023. Retrieved 25 May 2023.
Identifiers:
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.